ClinicalTrials.gg
CompletedNCT01986907TWEYESUpdated Jul 19, 2019Results posted

Safety and Tolerability of Ranibizumab in Mono/Bilateral Wet Age Related Macular Degeneration (w-AMD) Patients in Eyes With BCVA<2/10 and/or 2nd Affected Eye

A Phase 4 interventional study of ranibizumab in Wet Age Related Macular Degeneration, sponsored by Novartis Pharmaceuticals. Completed at 101 sites in Italy. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2019-07-19.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
1,049
Allocation
Non-randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 125 studies testing ranibizumab in Macular Degeneration — 3 open to participants now, 6 under way, 4 of them phase 3. Ranibizumab · Macular Degeneration.

Enrollment
4th of 124
1,049 · median 64
Started
2014
with 9 others
Phase 4
33 of 125
none open now
Registered
83rd of 125
by date
Lead sponsor
15 of 125
Novartis Pharmaceuticals

Among the 125 studies testing ranibizumab in Macular Degeneration, this one is the 4th largest by enrollment of the 124 interventional ones that give a count, is one of 10 that started in 2014, is one of 33 in phase 4, and was the 83rd registered.

Macular Degeneration

1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

3 of the 125 studies testing ranibizumab in Macular Degeneration are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ranibizumab

Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 165 Macular Degeneration studies recruiting now, 116 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 125 studies testing ranibizumab in Macular Degeneration, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and efficacy of ranibizumab in patients affected by wet age related macular degeneration (wAMD).

03

Conditions studied

  • Wet Age Related Macular Degeneration

Keywords

  • wet AMD
  • macular degeneration
  • ranibizumab
  • mono-bilateral
  • poor visual acuity
  • retinal disease
  • eye disease
  • Angiogenesis Inhibitors
  • Angiogenesis Modulating Agents
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Male or female patients aged 50 years or above Willing and capable to provide informed written consent Eye(s) eligible for ranibizumab treatment, with a BCVA below 2/10 due to wet AMD and/or Second eye eligible for ranibizumab treatment, with first eye treated (currently or previously) with ranibizumab, whichever BCVA. In bilateral wAMD patients, the second eye can be included only if the first eye has been treated at least 14 days before with ranibizumab

Exclusion criteria

Exclusion Criteria:

Active intraocular inflammation (grade trace or above) in either eye Any ocular or periocular active infection (current or suspected), e.g. conjunctivitis, keratitis, scleritis, uveitis, endophtalmitis, in either eye Risk factors for retinal pigment epithelial tear (including pigment epithelial retinal detachment) Ocular disorders that may confound interpretation of results compromise visual acuity or require medical or surgical intervention during the study period including cataract, retinal vascular occlusion, retinal detachment or macular hole Uncontrolled glaucoma in either eye (IOP ≥ 30 mmHg on medication or according to investigator's judgment) History of vitrectomy in the study eye History of stroke or Systemic treatment with any VEGF inhibitor in the 90 days prior to study enrollment Ocular treatment of the study eye with any anti-angiogenic drugs within 1 month prior to study enrollment Any intraocular surgery in the study eye within 28 days prior to enrollment Women of UNLESS using effective during treatment Pregnant or lactating women Simultaneous participation in a study that includes administration of any drug Known to ranibizumab or any component of the ranibizumab formulation Inability to comply with study procedures.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
1,049 participants (actual)

Study arms

  • Experimental
    Ranibizumab

    Administered as an Intravitreal injection

    Drug: ranibizumab

Interventions

  • All patients will receive ranibizumab 0.5 mg/0.05 ml according to approved label: treatment is given monthly until maximum VA is achieved (i.e. stable VA for three consecutive monthly assessments performed while on ranibizumab treatment). Thereafter according to approved label, patients should be monitored monthly for visual acuity and treatment is to be resumed when monitoring indicates loss of visual acuity due to disease activity. Monthly injections should then be administered until stable visual acuity is reached again for three consecutive monthly assessments (implying a minimum of two injections).

06

What researchers measure

Primary outcomes

  1. Number of Participants With Systemic Drug-related Adverse Events

    Monitoring and recording all adverse events, including serious adverse events.

    Time frame: Baseline to Month 12

  2. Number of Eyes With Ocular Drug-related Adverse Events

    Monitoring and recording all adverse events, including serious adverse events.

    Time frame: Baseline to Month 12

Secondary outcomes

  1. Overall Number of Ranibizumab Injections

    Time frame: Baseline to month 12

  2. Time Interval Between Injections in Bilateral Disease

    Mean number of days between two consecutive injections per eye

    Time frame: Baseline to month 12

  3. Mean Number of Injections Per Patient

    Number of injections per patient

    Time frame: Baseline to month 12

07

Results

Posted Jul 19, 2019

Participant flow

Patients were recruited from investigative sites located in Italy.

Participant flow — Overall Study
MilestoneRanibizumab
Started936
Completed774
Not completed162
Withdrew: Adverse event11
Withdrew: Unsatisfactory therapeutic effect24
Withdrew: Protocol violation4
Withdrew: Withdrawal by subject76
Withdrew: Lost to follow-up38
Withdrew: Death9

Outcome measures

PrimaryNumber of Participants With Systemic Drug-related Adverse Events

Monitoring and recording all adverse events, including serious adverse events.

Time frame:
Baseline to Month 12
Reported as:
Number · participants
Number of Participants With Systemic Drug-related Adverse Events
participantsRanibizumab
Serious Adverse Event3
Non Serious Adverse Event0
SecondaryOverall Number of Ranibizumab Injections
Time frame:
Baseline to month 12
Reported as:
Mean · injections per patient
Overall Number of Ranibizumab Injections
injections per patientRanibizumab
Overall Number of Ranibizumab Injections5.97 ± 3.62
SecondaryTime Interval Between Injections in Bilateral Disease

Mean number of days between two consecutive injections per eye

Time frame:
Baseline to month 12
Reported as:
Mean · days
Time Interval Between Injections in Bilateral Disease
daysRanibizumab
Time Interval Between Injections in Bilateral Disease51.94 ± 26.56
SecondaryMean Number of Injections Per Patient

Number of injections per patient

Time frame:
Baseline to month 12
Reported as:
Mean · injections
Mean Number of Injections Per Patient
injectionsRanibizumab OverallUnilaterally TretedBilaterally Treated
Mean Number of Injections Per Patient5.97 ± 3.625.35 ± 2.8810.55 ± 4.98
PrimaryNumber of Eyes With Ocular Drug-related Adverse Events

Monitoring and recording all adverse events, including serious adverse events.

Time frame:
Baseline to Month 12
Reported as:
Number · eyes
Number of Eyes With Ocular Drug-related Adverse Events
eyesRanibizumab
Serious Adverse Event1
Non Serious Adverse Event8

Adverse events

Collected over Adverse events are reported from time of first treatment until study exit (approximately 12 months). Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ranibizumab 0.5 mg9/936 (1%)63/936 (6.7%)76/936 (8.1%)
Most frequent serious events
Showing 10 of 68
Most frequent serious events
EventRanibizumab 0.5 mg
Femur fractureInjury, poisoning and procedural complications7/936
PneumoniaInfections and infestations5/936
Cardiac failureCardiac disorders3/936
Lung neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps)3/936
Transient ischaemic attackNervous system disorders3/936
AnaemiaBlood and lymphatic system disorders2/936
Atrial fibrillationCardiac disorders2/936
Intestinal obstructionGastrointestinal disorders2/936
OsteoarthritisMusculoskeletal and connective tissue disorders2/936
Cognitive disorderNervous system disorders2/936
Most frequent other events
Most frequent other events
EventRanibizumab 0.5 mg
Neovascular age-related macular degenerationEye disorders34/936
InfluenzaInfections and infestations15/936
Conjunctival haemorrhageEye disorders13/936
CataractEye disorders10/936
PyrexiaGeneral disorders10/936

Baseline characteristics

All treated participants

Age, Continuous
Age, Continuous(years)Ranibizumab
Mean78.68 ± 7.34
Age, Customized
Age, Customized(Participants)Ranibizumab
18 to less than 65 years33
65 to 74 years212
75 to 84 years483
85 years and older208
Sex: Female, Male
Sex: Female, Male(Participants)Ranibizumab
Female582
Male354
Treatment by Eye
Treatment by Eye(Participants)Ranibizumab
Unilateral treatment823
Bilateral treatment113
08

Study locations

101 sites
  • Novartis Investigative Site
    Alessandria, AL 15100, Italy
  • Novartis Investigative Site
    Casale Monferrato, AL 15033, Italy
  • Novartis Investigative Site
    Ancona, AN 60126, Italy
  • Novartis Investigative Site
    Acquaviva delle Fonti, BA 70021, Italy
  • Novartis Investigative Site
    Putignano, BA 70017, Italy
  • Novartis Investigative Site
    Terlizzi, BA 70038, Italy
  • Novartis Investigative Site
    Bergamo, BG 24127, Italy
  • Novartis Investigative Site
    Belluno, BL 32100, Italy
  • Novartis Investigative Site
    Bologna, BO 40138, Italy
  • Novartis Investigative Site
    Brescia, BS 25123, Italy
  • Novartis Investigative Site
    Desenzano del Garda, BS 25015, Italy
  • Novartis Investigative Site
    Bolzano, BZ 39100, Italy
  • Novartis Investigative Site
    Cagliari, CA 09124, Italy
  • Novartis Investigative Site
    Larino, CB, Italy
  • Novartis Investigative Site
    Caserta, CE 81100, Italy
  • Novartis Investigative Site
    Chieti, CH 66100, Italy
  • Novartis Investigative Site
    Ceva, CN 12073, Italy
  • Novartis Investigative Site
    Cuneo, CN 12100, Italy
  • Novartis Investigative Site
    Como, CO 22100, Italy
  • Novartis Investigative Site
    San Feramo Della Battaglia, CO 22020, Italy
  • Novartis Investigative Site
    Acireale, CT 95024, Italy
  • Novartis Investigative Site
    Catania, CT 95123, Italy
  • Novartis Investigative Site
    Catania, CT 95124, Italy
  • Novartis Investigative Site
    Catanzaro, CZ 88100, Italy
  • Novartis Investigative Site
    Forlì, FC 47100, Italy
  • Novartis Investigative Site
    Cona, FE 44100, Italy
  • Novartis Investigative Site
    Foggia, FG 71100, Italy
  • Novartis Investigative Site
    San Giovanni Rotondo, FG 71013, Italy
  • Novartis Investigative Site
    Genova, GE 16132, Italy
  • Novartis Investigative Site
    Genova, GE 16153, Italy
  • Novartis Investigative Site
    Rapallo, GE 16035, Italy
  • Novartis Investigative Site
    Crotone, KR 88074, Italy
  • Novartis Investigative Site
    Tricase, LE 73039, Italy
  • Novartis Investigative Site
    Terracina, LT 04019, Italy
  • Novartis Investigative Site
    Messina, ME 98125, Italy
  • Novartis Investigative Site
    Milazzo, ME 98057, Italy
  • Novartis Investigative Site
    Cinisello Balsamo, MI 20092, Italy
  • Novartis Investigative Site
    Legnano, MI 20025, Italy
  • Novartis Investigative Site
    Milano, MI 20100, Italy
  • Novartis Investigative Site
    Milano, MI 20122, Italy
  • Novartis Investigative Site
    Milano, MI 20123, Italy
  • Novartis Investigative Site
    Milano, MI 20132, Italy
  • Novartis Investigative Site
    Milano, MI 20142, Italy
  • Novartis Investigative Site
    Rozzano, MI 20089, Italy
  • Novartis Investigative Site
    Vizzolo Predabissi, MI 20070, Italy
  • Novartis Investigative Site
    Nuoro, NU 08100, Italy
  • Novartis Investigative Site
    Palermo, PA 90127, Italy
  • Novartis Investigative Site
    Palermo, PA 90146, Italy
  • Novartis Investigative Site
    Piacenza, PC 29100, Italy
  • Novartis Investigative Site
    Camposampiero, PD 35012, Italy
  • Novartis Investigative Site
    Monselice, PD 35043, Italy
  • Novartis Investigative Site
    Padova, PD 35100, Italy
  • Novartis Investigative Site
    Padova, PD 35128, Italy
  • Novartis Investigative Site
    Pescara, PE 65124, Italy
  • Novartis Investigative Site
    Citta' di Castello, PG 06012, Italy
  • Novartis Investigative Site
    Foligno, PG 06034, Italy
  • Novartis Investigative Site
    Perugia, PG 06100, Italy
  • Novartis Investigative Site
    Pordenone, PN 33170, Italy
  • Novartis Investigative Site
    Parma, PR 43100, Italy
  • Novartis Investigative Site
    Pavia, PV 27100, Italy
  • Novartis Investigative Site
    Reggio Calabria, RC 89124, Italy
  • Novartis Investigative Site
    Correggio, RE 42015, Italy
  • Novartis Investigative Site
    Reggio Emilia, RE 42123, Italy
  • Novartis Investigative Site
    Civitavecchia, RM 00053, Italy
  • Novartis Investigative Site
    Roma, RM 00133, Italy
  • Novartis Investigative Site
    Roma, RM 00161, Italy
  • Novartis Investigative Site
    Roma, RM 00168, Italy
  • Novartis Investigative Site
    Roma, RM 00184, Italy
  • Novartis Investigative Site
    Roma, RM 00186, Italy
  • Novartis Investigative Site
    Roma, RM 00189, Italy
  • Novartis Investigative Site
    Riccione, RN 47838, Italy
  • Novartis Investigative Site
    Eboli, SA 84025, Italy
  • Novartis Investigative Site
    Salerno, SA 84131, Italy
  • Novartis Investigative Site
    Sondrio, SO 23100, Italy
  • Novartis Investigative Site
    Sarzana, SP 19038, Italy
  • Novartis Investigative Site
    Sassari, SS 07100, Italy
  • Novartis Investigative Site
    Savona, SV 17100, Italy
  • Novartis Investigative Site
    Taranto, TA 74100, Italy
  • Novartis Investigative Site
    Teramo, TE 64100, Italy
  • Novartis Investigative Site
    Torino, TO 10122, Italy
  • Novartis Investigative Site
    Torino, TO 10152, Italy
  • Novartis Investigative Site
    Torino, TO 10153, Italy
  • Novartis Investigative Site
    Terni, TR 05100, Italy
  • Novartis Investigative Site
    Trieste, TS 34129, Italy
  • Novartis Investigative Site
    Conegliano, TV 31015, Italy
  • Novartis Investigative Site
    Treviso, TV 31100, Italy
  • Novartis Investigative Site
    Udine, UD 33100, Italy
  • Novartis Investigative Site
    Busto Arsizio, VA 21052, Italy
  • Novartis Investigative Site
    Somma Lombardo, VA 21019, Italy
  • Novartis Investigative Site
    Varese, VA 21100, Italy
  • Novartis Investigative Site
    Santorso, VI 36014, Italy
  • Novartis Investigative Site
    Vicenza, VI 36100, Italy
  • Novartis Investigative Site
    Legnago, VR 37045, Italy
  • Novartis Investigative Site
    Negrar, VR 37024, Italy
  • Novartis Investigative Site
    Verona, VR 37126, Italy
  • Novartis Investigative Site
    Borgomanero, 28021, Italy
  • Novartis Investigative Site
    Galliate, 28066, Italy
  • Novartis Investigative Site
    Napoli, 80131, Italy
  • Novartis Investigative Site
    Napoli, 80132, Italy
  • Novartis Investigative Site
    Napoli, 80138, Italy

Showing the first 100 of 101 sites. Choose a country and city above to see the rest.

09

References and documents

Individual participant data

Plan to share: Undecided — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2014 to primary completion in Jun 2016, 27 months.

Results were first posted in Jul 2019, 3 years 1 month after primary completion.

Of 24 industry-sponsored phase 4 interventional studies under Macular Degeneration, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 36. This study's 27 months is close to that.

Counting every sponsor, half of 45 studies reached it within 26 months; a quarter within 14 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2013
First posted
Nov 19, 2013
StartActual
Mar 4, 2014
Primary completionActual
Jun 15, 2016
CompletionActual
Jun 15, 2016
Results first posted
Jul 19, 2019
Last update
Jul 19, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 19, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01986907
Responsible party
Sponsor
First posted
Nov 19, 2013
Start date
Mar 4, 2014
Primary completion
Jun 15, 2016
Completion
Jun 15, 2016
Results posted
Jul 19, 2019
Last update
Jul 19, 2019

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ranibizumab

Start the discussion